Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2019-05-07 Capital/Financing Update
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Mereo BioPharma Group plc. It announces the issuance of warrants related to revisions in a loan agreement, which is a financing activity. The document is not a full financial report but an announcement of a capital/financing update. It contains specific details about the warrants issued, the number of shares, exercise price, and related parties. There is no indication of it being an earnings release, annual report, or other report types. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2019-05-07 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing by Mereo BioPharma Group plc, which is a report of a foreign private issuer pursuant to SEC rules under the Securities Exchange Act of 1934. The content primarily announces the intention of the Trustee of the Employee Benefit Trust to purchase shares for the benefit of the Trust, funded by a loan agreement. There is no detailed financial data, earnings information, or comprehensive report content. The document is an announcement of a financing-related activity (share purchases by Trustee funded by a loan), which fits best under Capital/Financing Update (CAP). The document length is over 6000 characters, indicating it is not a mere brief announcement or report publication notice. Therefore, the classification is CAP with high confidence.
2019-05-07 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Mereo BioPharma Group plc. It announces the intention of the Trustee of the Employee Benefit Trust to purchase shares in the market to meet future obligations under the company's share schemes. The content focuses on a capital transaction related to share purchases funded by a loan agreement. There are no financial statements or detailed financial results presented, nor is this an announcement of voting results, management changes, or legal proceedings. The document is not a full annual or interim report but rather an update on financing activity related to share purchases. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about financing activity, not just a brief announcement or certification, supporting a high confidence level.
2019-05-03 English
FORM 6-K
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed by Mereo BioPharma Group plc, which is a report of a foreign private issuer pursuant to SEC rules. The content specifically details a notification of director dealing, describing a purchase of shares by John Richard, Head of Corporate Development. The document includes transaction details such as volume, price, and date. There is no financial report or earnings data, but rather a disclosure of insider share transactions. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3317 characters, which is consistent with a brief notification rather than a full report. Therefore, the correct classification is DIRS with high confidence.
2019-05-03 English
Intention to Purchase Shares by Trustee of EBT
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Mereo BioPharma Group plc regarding the intention of the Trustee of its Employee Benefit Trust to purchase company shares in the market to satisfy future share scheme obligations. This falls under the category of a company's transaction in its own shares (or shares held for its benefit), which is classified as 'Transaction in Own Shares' (POS).
2019-05-03 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a formal notification of a share purchase by a member of the company's management (John Richard, Head of Corporate Development). It explicitly uses the title 'Notification of Director Dealing' and follows the standard EU Market Abuse Regulation disclosure format for transactions by persons discharging managerial responsibilities. This aligns perfectly with the definition for 'Director's Dealing'.
2019-05-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.